TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

TRACON Pharmaceuticals (NASDAQ: TCON) announced that its President and CEO, Charles Theuer, M.D., Ph.D., will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, scheduled from January 10-13, 2022. The presentation will be accessible on-demand starting at 7:00 AM Eastern Time on January 10, 2022, via the Company’s website. TRACON focuses on developing targeted cancer therapies through a cost-efficient, CRO-independent platform, with a pipeline that includes Envafolimab, YH001, TRC102, and TJ004309.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BIOCONNECT Virtual Conference, being held January 10-13, 2022.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, January 10, 2022, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:	Investor Contact:
Mark Wiggins	Brian Ritchie
Chief Business Officer	LifeSci Advisors LLC
(858) 251-3492	(212) 915-2578
mwiggins@traconpharma.com	britchie@lifesciadvisors.com

FAQ

What is TRACON Pharmaceuticals' upcoming presentation at the H.C. Wainwright BIOCONNECT Virtual Conference?

Charles Theuer, M.D., Ph.D., will present an overview of TRACON Pharmaceuticals at the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022.

When will the TRACON Pharmaceuticals presentation be available for viewing?

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on January 10, 2022.

What are the key products in TRACON Pharmaceuticals' pipeline?

TRACON's pipeline includes Envafolimab, YH001, TRC102, and TJ004309, all aimed at treating various forms of cancer.

How does TRACON Pharmaceuticals develop its cancer therapies?

TRACON utilizes a capital-efficient, CRO-independent product development platform to create targeted cancer therapies.

What is the significance of the H.C. Wainwright BIOCONNECT Virtual Conference for TRACON Pharmaceuticals?

The conference provides TRACON Pharmaceuticals an opportunity to present its corporate strategy and pipeline to potential investors and partners.